Effective Oct. 1 for five years, the Centers for Medicare & Medicaid Services will pay Average Sales Price plus 8%, rather than ASP plus 6%, for biosimilars whose average sales price does not exceed the price of the reference biological product. The payment increase was included in the Inflation Reduction Act of 2022. For new biosimilars that qualify, the five-year period will begin on the first day of the calendar quarter for which ASP payment for that biosimilar begins under Medicare Part B.

Related News Articles

Headline
Medicare open enrollment for 2026 began Oct. 15 and runs through Dec. 7. During the annual enrollment period, Medicare-eligible individuals can check their…
Headline
Members of the AHA Board of Trustees Oct.14 participated in a panel on the future of rural health care during the Sanford Rural Health Summit in Sioux Falls, S…
Headline
AHA leaders today participated in Sanford Health's fourth annual Summit on the Future of Rural Health Care in Sioux Falls, S.D. Bill Gassen, Sanford Health…
Headline
Applications for the Rural Health Transformation Program are due Nov. 5 to the Centers for Medicare & Medicaid Services. The program will fund $50 billion…
Headline
The federal government shutdown will continue as the Senate Oct. 3 failed to adopt a government funding deal. The latest attempt to pass the House-passed…
Headline
The federal government shut down Oct. 1 following a failed Senate vote on the House-passed continuing resolution to fund the government by midnight Sept. 30.…